Dianthus Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $41.3M | $27.9M | $5.8M |
| SG&A Expense | $18.6M | $7.8M | $3.5M |
| Operating Income | $-60.0M | $-35.7M | $-9.3M |
| Operating Margin | — | — | — |
| Interest Expense | — | — | $163.0K |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-57.5M | $-35.5M | $-9.4M |
| Net Margin | — | — | — |
| EPS (Basic) | $-0.09 | $-0.53 | $-1.81 |
| EPS (Diluted) | $-0.09 | $-0.53 | $-1.81 |
| Shares Outstanding (Basic) | 1.20B | 84.6M | — |
| Shares Outstanding (Diluted) | 1.20B | 84.6M | — |
| Dividends Per Share | — | — | — |